

# References

---

- Abbott, F.M. (1989), 'Protecting first world assets in the third world: intellectual property in the GATT multilateral framework', *Vanderbilt Journal of Transnational Law*, **22**(4), 689–744.
- Abbott, F.M. (1998a), 'The enduring enigma of TRIPs: a challenge for the world trading system – editorial', *Journal of International Economic Law*, **1**(4), 497–521.
- Abbott, F.M. (1998b), 'First report (Final: 1997) to the Committee on International Trade Law of the International Law Association on the Subject of parallel importation', *Journal of International Economic Law*, **1**(4), 607–36.
- Ager, B. (1998), (Director General EFPIA), 'TRIPsII – Millennium Round', circular addressed to Members of EFPIA Intellectual Property Committee, Brussels: EFPIA, 11 September.
- Ager, B. (1999), (Director General EFPIA), 'TRIPsII – Millennium Round – Update', Brussels: EFPIA, 13 October.
- Aizenberg, A. (2000), 'Teva CEO: in 1999 we have established our position as the world's leading generic company (Hebrew Translation)', *Maariv*, Tel-Aviv, 15 February.
- Almeida, R.P. (1990), 'The "new" Intellectual Property Regime and its economic impact on developing countries', in G. Sacerdoti (ed.), *Liberalization of Services and Intellectual Property in the Uruguay Round*, Switzerland: University Press Fribourg, pp. 74–113.
- Andersen S.S. and K.A. Eliassen (eds) (1993), *Making Policy in Europe*, London: Sage.
- Andrews, L.E. (2001), 'Bayer's antibiotics adds to its woes', *International Herald Tribune*, 19 October, p. 14.
- Armitage A.R. (1992), 'US developments: crossroads for a patent system', *News – Patents and Trademarks: Developments in Industrial Property Rights*, **21**, January, 10–13.
- Arrow, K. (1951), *Social Choice and Individual Values*, New Haven: Yale University.
- Arrow, K. (1962), 'Economic welfare and the allocation of resources for invention', in National Bureau of Economic Research (ed.), *The Rate and Direction of Inventive Activity: Economic and Social Factors*, Princeton, New Jersey: Princeton University Press, pp. 609–26.

- Association of the British Pharmaceutical Industry (ABPI) (1996), 'Pharmaceutical industry issues', London: ABPI.
- Association of the British Pharmaceutical Industry (ABPI) (1998), 'Structures and plans update', London: ABPI, April.
- Association of the British Pharmaceutical Industry (ABPI) (1999a), 'ABPI statement on proposals to NICE', London: ABPI, 3 February.
- Association of the British Pharmaceutical Industry (ABPI) (1999b), Press release: 'New PPRS Signed', London: 21 July.
- Association of the British Pharmaceutical Industry (ABPI) (2000a), *ABPI 1999/2000 Handbook*, London: ABPI.
- Association of the British Pharmaceutical Industry (ABPI) (2000b), Press release: 'Pharmaceutical task force: first meeting', London: ABPI, 13 April.
- Association of the British Pharmaceutical Industry (ABPI) (2000c), Press release: "Tough negotiations" promised on PPRS by industry', London: ABPI, 14 July.
- Association of the British Pharmaceutical Industry (ABPI) (2000d), Press release: 'Progress on government pharmaceutical industry competitiveness task force', London: ABPI, 14 July.
- AstraZeneca (2003), *Annual Review 2002*, London: AstraZeneca.
- Bachrach, P. and M. Baratz (1962), 'The two faces of power', *American Political Science Review*, **56**, 947–52.
- Bailey, M.T. (1992), 'Do physicists use case studies? Thoughts on public administration research', *Public Administration Review*, **52**(4), 47–54.
- Ballance, R., J. Pogany and H. Forstner (1992), United Nations Industrial Development and Organisation (UNIDO) (eds) *The World's Pharmaceutical Industries*, Aldershot, UK and Brookfield, US: Edward Elgar.
- Bale, H., (1998), (Director General, IFPMA), 'The conflicts between parallel trade and product access and innovation: the case of pharmaceuticals', *Journal of International Economic Law*, **1**(4) 637–53.
- Barzel, Y. (1968), 'Optimal timing of innovation', *The Review of Economics and Statistics*, **50**, August, 348–55.
- Bayer AG. (2001a), Press Release: 'Canadian Government acknowledges patent protection for Cipro', Leverkusen, Germany: 23 October.
- Bayer AG. (2001b), Press Release: 'Bayer, NHS complete Cipro agreement: Americans assured of ample supplies of Cipro to combat war on bioterrorism', Leverkusen, Germany: 25 October.
- Baynon, K. (2000), 'Feeling confident in the countdown for patent expiry', *Scrip Magazine*, January.
- BBC News (2001), 'Anthrax Drug Sparks Row over Patent', 20 October, electronic version.
- Beck, R.L. (1981), 'Competition for patent monopolies', *Research in Law and Economics*, **3**, 91–110.

- Beier, F. and G. Schricker (eds) (1989), *GATT or WIPO? New Ways on the International Protection of Intellectual Property Rights*, Munich: VCH.
- Bentham, J. (1843), 'A manual of political economy', in J. Bowring (ed.), *The Collected Works of Jeremy Bentham*, vol.III, Edinburgh: W. Tait.
- Beresford, B. (2001), 'Drugs giants prepare for war', *The Guardian*, 6 March.
- Beton, J. (1987), 'The Importance of Third World Implantation of TRIPs', Zeneca plc, 12 November.
- Beton, J. (1998), 'Aide Memoire: Implementation of TRIPs and the New Trade Round – Visits by UNICE and IPC to WTO, WIPO and the Commission, 19–21 October', London, 30 October.
- Beton, J. and L. Saylor (1996), 'Why the TRIPs agreement', in International Chamber of Commerce (ed.), *Intellectual Property and International Trade*, Paris: ICC, pp. 12–17.
- BEUC (2000), *Access to Medicines in the Developing World*, Brussels: 19 December.
- Blakeney, M. (1996), *Trade Related Aspects of Intellectual Property Rights: A Concise Guide to the TRIPs Agreement*, London: Sweet and Maxwell.
- Blakeney, M. (1999), 'What is traditional knowledge? Why should it be protected? Who should protect it? For whom?: understanding the value chain', in: *Round Table on Intellectual Property and Traditional Knowledge – 1 and 2 November 1999*, Geneva: WIPO – International Bureau, 6 October.
- Bolkestein, F. (2000), (European Commissioner for Internal Market), Speech: The Protection of Industrial Property In Europe and Its Place in the World, Alicante: 29 May.
- Bond R.S. and D.F. Lean (1977), *Sales, Promotion and Product Differentiation in Two Prescription Drug Markets*, Washington DC: Federal Trade Commission.
- Booth, J. (2001), 'Asian nations remain split before WTO talks', *Wall Street Journal Europe*, 8 November, p. 3.
- Bossche, P. (1997), 'The European Community and the Uruguay Round Agreements', in A.O. Sykes and J.H Jackson (eds), *Implementing the Uruguay Round*, Oxford: Clarendon Press, pp. 23–102.
- Boyle, J. (2001), 'Whigs and hackers in Cyberspace – copyrights regulations before the European Parliament should be treated as sceptically as they were by the Victorians', *Financial Times*, 12 February.
- Braithwaite, J. and P. Drahos (2000), *Global Business Regulation*, Cambridge: Cambridge University Press.
- Branthwaite, A. and T. Downing (1995), 'Marketing to doctors – the human factor', *Scrip Magazine*, March.
- BruECKmann, A. (1990), 'Intellectual property protection in the European Community', in Francis W. Rushing and Carole G. Brown (eds), *Intellectual*

- Property Rights in Science, Technology, and Economic Performance*, Boulder, San Francisco: Westview Press, pp. 291–310.
- Buchanan, J.M. (1984), 'Constitutional restrictions on the power of government', in J.M. Buchanan and R.D. Tollison (eds), *The Theory of Public Choice II*, Ann Arbor: University of Michigan Press.
- Buchanan J.M. and G. Tullock (1962), *The Calculus of Consent: Logical Foundations of Constitutional Democracy*, Ann Arbor: University of Michigan Press.
- Bundesverband der Pharmazeutischen Industrie (BPI) (1998), *Pharmaceutical Data 98*, Frankfurt: BPI.
- Burns, J. and D. Pilling (1999), 'Dirty tricks in the international drug industry', *Financial Times*, 10 May.
- Burstall, M.L. and I.S.T. Senior (1992), *Undermining Innovation: Parallel Trade in Prescription Medicines*, London: IEA Health and Welfare Unit.
- BusinessWeek* (2003), 'The 1000 Global – the World's Most Valuable Companies' 14 July, European Edition.
- Business Software Alliance (1999), *1998 Global Software Piracy Report*, BSA, May.
- Campolini, M. (1998), 'Millennium Round and TRIPs Implementation', Letter Addressed to Mr Jerome Chauvin, UNICE, Brussels: 10 November.
- Canadian Department of Health (2001), 'News release: Health Canada and Bayer. Inc confirm supply agreement for Ciprofloxacin Hydrochloride', 22 October.
- Chall'u, P. (1991), 'The consequences of pharmaceutical product patenting', *World Competition*, **15**(2).
- Chamberlin, E.H. (1947), *The Theory of Monopolistic Competition*, 5th edn, Cambridge, Massachusetts: Harvard University Press.
- Chartrand, S. (2000), 'Patent on cloning may cover people', *Herald Tribune*, 27 June.
- Chin, J.C. and G.M. Grossman (1990), 'Intellectual Property Rights and North–South Trade', in R. Jones and A. Krueger (eds), *The Political Economy Of International Trade*, Oxford: Basil Blackwell, pp. 90–197.
- Colitt R. (2001), 'Brazil and Roche agree deal on Aids drug price cut after threat to patent', *Financial Times*, 1 September.
- Collie, L. (1993), 'Business lobbying in the European Community: the Union of Industrial and Employers' Confederation of Europe', in S. Mazey and J. Richardson (eds), *Lobbying in the European Community*, Oxford and New York: Oxford University Press, pp. 213–26.
- Commission of the European Communities (1988), *Green Paper on Copyright and the Challenge of Technology: Copyright Issues Requiring Immediate Attention*, Brussels.

- Commission of the European Communities (1992), *Impediments to Parallel Trade in Pharmaceuticals Within the European Community*, Brussels.
- Commission of the European Communities (1997), *Promoting Innovation Through Patents – Green Paper on the Community Patent System in Europe*, Brussels.
- Commission of the European Communities (1998), *Green Paper – Combating Counterfeiting and Piracy in the Single Market*, Brussels: 15 October, document number: COM(98) 569 Final.
- Commission of the European Communities (1999), *Communication from the Commission to the Council and the European Parliament – The EU Approach to the Millennium Round*, Brussels: 8 July, document number: Com(1999)331-C5-0155/1999–1999/2149(COS).
- Commission of the European Communities (2000), *Qualified Majority Voting: Common Commercial Policy*, Inter-Governmental 2000 Conference, Nice, December.
- Commission of the European Communities (2001a), *Legal Issues Related to Compulsory Licensing Under the TRIPs Agreement*, Brussels.
- Commission of the European Communities (2001b), *Questions on TRIPs and Data Exclusivity – An EU Contribution*, Brussels.
- Commission of the European Communities (2001c), *Review of the Provisions of Article 27.3(b) of the TRIPs Agreement – Draft Communication by the European Communities and Their Member States on the Relationship Between the Convention on Biodiversity and the TRIPs Agreement – Submitted by the Commission to the Article 133 Committee*, Brussels: 23 February.
- Commission of the European Communities – DG Internal Market (1998), *Special Sectoral Report – Industrial Property*, Brussels: October.
- Commission of the European Communities – DG Trade (1998a), *The European Union and the Protection of Intellectual Property*, Brussels: DG Trade website: [www.europa.eu.int/comm/dgs/trade/index\\_en.htm](http://www.europa.eu.int/comm/dgs/trade/index_en.htm), October.
- Commission of the European Communities – DG Trade (1998b), Press Release: ‘European Union launches WTO Panel against Canada for insufficient patent protection’, Brussels: 12 November, document number: IP/98/989.
- Commission of the European Communities – DG Trade (1999a), *The European Union and the Protection of Intellectual Property*, Brussels: DG Trade website: [www.europa.eu.int/comm/dgs/trade/index\\_en.htm](http://www.europa.eu.int/comm/dgs/trade/index_en.htm), May.
- Commission of the European Communities – DG Trade (1999b), *EC Approach to Trade-Related Aspects of Intellectual Property*, DG Trade website: [www.europa.eu.int/comm/dgs/trade/index\\_en.htm](http://www.europa.eu.int/comm/dgs/trade/index_en.htm), May.
- Commission of the European Communities – DG Trade (1999c), *Multilateral & International Trade Issues – International Protection for Intellectual Property Rights – Overview*, DG Trade website: [www.europa.eu.int/comm/dgs/trade/index\\_en.htm](http://www.europa.eu.int/comm/dgs/trade/index_en.htm), November.

- Commission of the European Communities – DG Trade (2000a), *Multilateral Issues – Intellectual Property – Comments on Transatlantic Consumer Dialogue on 10–12 February 2000 – Recommendations on Intellectual Property Rights and Access to Medicines*, Brussels: February.
- Commission of the European Communities – DG Trade (2000b), *Seattle Conference Preparation: EC Approach to Trade-Related Aspects of Intellectual Property*, Brussels: April.
- Commission of the European Communities – DG Trade (2000c), *Multilateral & International Trade Issues – International Protection for Intellectual Property Rights – Intellectual Property Rights are Valuable and Must be Protected*, DG Trade website: [www.europa.eu.int/comm/dgs/trade/index\\_en.htm](http://www.europa.eu.int/comm/dgs/trade/index_en.htm), June.
- Commission of the European Communities – DG Trade (2000d), *The Reform of Article 133 by the Nice Treaty – The Logic of Parallelism*, DG Trade website: [www.europa.eu.int/comm/dgs/trade/index\\_en.htm](http://www.europa.eu.int/comm/dgs/trade/index_en.htm), December.
- Commission of the European Communities – DG Trade (2001a), *A New Round for Harnessed, Equitable Globalisation*, Brussels: October.
- Commission of the European Communities – DG Trade (2001b), *Towards Better Recognition of Intellectual Property Rights*, Brussels: October.
- Commission of the European Communities – DG Trade (2001c), *Fourth Stakeholders' Meeting on 'Trade and Access to Medicines'*, [http://trade-info.cec.eu.int/civil\\_soc/documents/meeting/me-25-health6nov.pdf](http://trade-info.cec.eu.int/civil_soc/documents/meeting/me-25-health6nov.pdf), 6 November.
- Commission of the European Communities – DG Trade (2001d), *Outcome of WTO Ministerial Conference in Doha: Comprehensive Assessment of Results for the European Union*, Brussels: 19 November.
- Commission of the European Communities, Economic Advisory Group (1985), *The Community's Pharmaceutical Industry*, Brussels.
- Consolidated Version of the Treaty Establishing the European Community (1997), Luxembourg.
- Cookson, C. (1998), 'Another golden year in prospect', *Financial Times*, Global Business Outlook, 13 January.
- Cooper, H. and G. Winestock (2001), 'How activists outmanoeuvred drug makers in WTO deal', *Wall Street Journal Europe*, 15 November, p. 6.
- Cooper, H., R. Zimmerman and L. McGinley (2001), 'Drugs maker's fight for patent rights put them in a vice', *Wall Street Journal Europe*, 5 March.
- Cooter, R. and T. Ulen (eds) (1998), *Law and Economics*, London: Glenview.
- Cornish, W.R. (1999), *Intellectual Property Rights: Patents, Copyrights, Trademarks and Allied Rights*, 4th edn, London: Sweet & Maxwell.
- Correa, C.M. (2000), *Intellectual Property Rights, the WTO and Developing Countries*, New York: Zed Books.
- Corrigan, T. (1999), 'Stocks in US drug groups catch a cold', *Financial Times*, 26 January, p. 24.

- Council of the European Communities (1989), *Council Agreement relating to community patents (89/695/EEC) done at Luxembourg on 15 December 1989*, Official Journal of the European Community, (OJ) L401, 30 December.
- Council of the European Communities (1992), *Council Regulation (EEC) No 1768/92 of 18 June 1992 Concerning the creation of Supplementary Protection Certificate for Medicinal Products*, 18 June.
- Council of the European Union (1986), *Council Regulation (EEC) No 3842/86 of 1 December 1986 Laying down Measures to Prohibit the Release for Free Circulation of Counterfeit Goods* (OJ) L357, 18 December, p. 1.
- Council of the European Union (1994a), *Council Regulation (EC) No 3286/94 of 22 December 1994 laying down Community procedures in the field of the common commercial policy in order to ensure the exercise of the Community's rights under international trade rules, in particular those established under the auspices of the World Trade Organisation*, Brussels: December.
- Council of the European Union (1994b), *Council Regulation (EC) No 40/94 of 20 December 1993 on the Community trade mark*, Brussels: 20 December.
- Council of the European Union (1999), *Agreement on Trade, Development and Cooperation Between the European Community and its Member States, of the one part, and the Republic of South Africa, of the other part*, Brussels: 9 July, document number: 8731/99.
- Council of the European Union (2000a), *Exhaustion of Trade Mark Rights*, Brussels: 28 February, document number: 6720/00.
- Council of the European Union (2000b), *Parallel Imports/Exhaustion of Trade Mark Rights*, Brussels: 5 May, document number: 8052/00.
- Council of the European Union (2000c), *List of Committees and Working Parties involved in the Council's Preparatory Work*, Brussels: 16 May.
- Council of the European Union – Enlargement Group (2000), *Enlargement – Preparation of the Next Accession Conferences at Deputy Level with Cyprus Hungary, Poland, Estonia, the Czech Republic and Slovenia – Annex Draft*, 3 March, Ref. ELARG 29, document number: 6584/00.
- Cowles, M.G. (1998), 'The changing architecture of big business', in J. Greenwood and M. Aspinwall (eds), *Collective Action in the European Union*, New York: Routledge, pp. 108–25.
- Dasgupta, P. and J. Stiglitz (1980), 'Industrial structure and the nature of innovation activity', *The Economic Journal*, **90**(358), June, 266–93.
- Davies, W. (1967), *The Pharmaceutical Industry – A Personal Study*, London: Pergamon Press.
- Degli, N. (2001), 'Drug companies put South Africa in the dock', *Financial Times*, 4 March.
- Degli, N. and D. Pilling (2001a), 'Drugs groups hope courts will remedy broken rights', *Financial Times*, 5 March.

- Degli, N. and D. Pilling (2001b), 'Aids patents suit to be halted', *Financial Times*, 18 April.
- Delvin, J. and P. Helmsley (1997), 'Management views on industry issues, pressure and consultants', *Scrip Magazine*, 16 June, p. 183.
- Department for International Development, United Kingdom (2000), *White Paper on International Development – Eliminating World Poverty: Making Globalisation Work for the Poor*, London: December.
- Department of Trade and Industry, United Kingdom (1999), *The UK and the World Trade Organisation: An Introduction to the Next Round*, London: DTI, May.
- Department of Trade and Industry, United Kingdom (2000), *World Trade and International Trade Rules – Intellectual Property*, London: DTI, 8 December.
- Diwan, I. and D. Rodrik (1989), *Patents, Appropriate Technology, and North–South Trade*, PPR Working Papers, Washington DC: The World Bank.
- Doane, M.L. (1994), 'TRIPS and international intellectual property protection in an age of advancing technology', *American University Journal of International Law and Policy*, 9(2), 465–97.
- Doern, B.G. (1998), *Global Change and Intellectual Property Agencies*, New York: Pinter.
- Downs, A. (1957), *An Economic Theory of Democracy*, New York: Harper and Row.
- Dulforce, W. (1988), 'EC presents patents proposals to GATT', *Financial Times*, 8 July.
- Dunleavy P. (1991), *Democracy, Bureaucracy and Public Choice*, London: Harvester Wheatsheaf.
- Dyer, G. and A. Michaels (2001), 'A bitter pill for the drug makers', *Financial Times*, 23 October, p. 19.
- Dyer, G. and K. Warn (2001), 'Bayer upset as Canada overrides patent law', *Financial Times*, 20 October.
- Eckstein, H. (1975), 'Case study and theory in political science', in Fred I. Greenstein and Nelson W. Polsby (eds) *Handbook of Political Science, vol. 1, Political Science: Scope and Theory*, Reading, Mass: Addison Wesley.
- Economic and Social Commission for Western Asia (ESCWA) (1998), *Challenges and Opportunities of the New International Trade Agreements (Uruguay Round) for ESCWA Member Countries in Selected Sectors: Implications of WTO/TRIPs for Technology Transfer in the Pharmaceutical Industry*, New York: United Nations.
- Economic Council of Canada (1971), *Report on Intellectual and Industrial Property*, Ottawa: January.



- The Economist* (1992), *Warning Shots: India and America Fall Out*, London: 9 May.
- The Economist* (1998), *A Survey of the Pharmaceutical Industry*, London: 21–27 February.
- The Economist* (1999a), *A Survey of Innovation in Industry*, 20–26 February.
- The Economist* (1999b), *Balms for the Poor*, 14–20 August, pp. 63–5.
- The Economist* (1999c), *Lesson from Microsoft*, London: 6–12 March, pp. 21–2.
- The Economist* (2000), ‘Who owns your genes?’ in: *The Human Genome – Survey*, London: 1–7 July.
- The Economist* (2001a), *Science and Profit*, London: 17–23 February, pp. 19–20.
- The Economist* (2001b), *Drugs, Patents and Aids*, London: 10–16 March, pp. 43–4.
- The Economist* (2001c), *Big Music Fights Back*, London: 16–22 June, pp. 67–8.
- Edwards, C.D. (1949), *Maintaining Competition – Requisites of Governmental Policy*, New York: McGraw-Hill.
- Edwards, H.R. (1962), *Competition and Monopoly in the British Soap Industry*, Oxford: Clarendon Press.
- Eli Lilly and Company (1997), ‘1997 Annual Report’, Indianapolis, Indiana: Eli Lilly.
- Emmert, F. (1990), ‘Intellectual property in the Uruguay Round – negotiating strategies of the Western industrialised countries’, *Michigan Journal of International Law*, 11(4), Summer, pp. 1317–99.
- Engel, R.L. (1985), ‘Patent enforcement: the uncertainties of patent litigation’, in G.S. Tolley, J.F. Oehmke and J.H. Hodge (eds), *The Economics of R&D Policy*, New York: Praeger, pp. 95–101.
- European Chemical Industry Council (1998), ‘The chemical industry statement on TRIPs and the environment’, Brussels: CEFIC, October.
- European Chemical Industry Council (2000a), *Annual Report 1999*, Brussels: CEFIC.
- European Chemical Industry Council (2000b), ‘Focus on CEFIC – Statutory Bodies’, Brussels: CEFIC.
- European Communities and their Member States (2001), ‘Communication to the TRIPs Council: the Relationship Between the Provisions of the TRIPs Agreement and Access to Medicines’, Brussels: 13 June.
- European Communities and their Member States, Working Group on the Interaction Between Trade and Competition Policy (1998), *Communication on the Relationship Between the Trade Related Aspects of Intellectual Property Rights and Competition Policy, and Between Investment and Competition Policy*, Brussels: 15 September, document number: 98-73720

- European Court of Justice (1994), 'Opinion 1/94 of the Court of Justice: Competence of the Community to conclude international agreements concerning services and the protection of intellectual property – Article 228(6) of the EC Treaty', Luxembourg: 15 November.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1997a), *Annual Report 1997*, Brussels: EFPIA.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1997b), 'Trademarks and the centralised registration system procedures for medical products, second position paper', Brussels: EFPIA, August.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1998a), *Annual Report 1998*, Brussels: EFPIA.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1998b), *The Pharmaceutical Industry in Figures*, Brussels: EFPIA.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999a), *The Pharmaceutical Industry in Figures – Key Data 1999 Update*, Brussels: EFPIA.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999b), 'About the industry – intellectual property', Brussels: EFPIA website: <http://www.efpia.org>.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999c), 'Activities and accomplishments', Brussels: EFPIA website: <http://www.efpia.org>.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999d), 'Structure and organisation', Brussels: EFPIA website: <http://www.efpia.org>.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999e), 'Position paper: TRIPs and the Millennium Round', Brussels: EFPIA, June.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999f), Position statement, 'Korea: Trade barriers to international pharmaceuticals', Brussels: EFPIA, June.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999g), Position paper, 'International exhaustion trademarks and pharmaceuticals', Brussels: EFPIA, August.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999h), Position statement, 'Taiwan: trade barriers to international pharmaceuticals', Brussels: EFPIA, September.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999i), Position paper, 'TRIPs and the Millennium Round', Brussels: EFPIA, October.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999j), Press release, 'The pharmaceutical industry is contributing to improve

- healthcare in developing countries and participates in global actions that pave the way for better global public health', Brussels: 23 November.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2000a), Press release, 'European pharmaceutical industry disappointed by the WTO Panel decision on the EU/Canada patent dispute', Brussels: 20 March.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2000b), Generic Working Group, Position papers, 'Generic substitution and regulatory data protection', Brussels: EFPIA, June.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2000c), 'Prodi at the EFPIA Meeting: Products Better and Faster to Patients', Brussels: EFPIA, 22 June.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2000d), "'It is vital that the European commission moves further along the market liberalisation route of the pharmaceutical sector', says Jorge Gallardo, EFPIA President to Romano Prodi', Brussels: EFPIA: 22 June.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2000e), Position paper, 'TRIPs Article 39.3 (Protection of Undisclosed Data) – a critical issue for the continued development of safe and innovative medicines for patients', Brussels: EFPIA, November.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2001a), 'Access to medicines: the right policy prescription', Brussels: EFPIA.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2001b), 'Pharmaceutical industry welcomes amicable settlement reached by all parties in South African court case: patients are real winners', Brussels: EFPIA, 19 April.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2001c), Position paper, 'WTO Millennium Round', Brussels: EFPIA, July.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2001d), '5 Common misunderstandings about patents, TRIPs, compulsory licensing, parallel trade and local production', Brussels: EFPIA, September.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2001e), 'Pharmaceutical Industry statement regarding Doha political declaration on TRIPs agreement and public health', Brussels: EFPIA, 14 November.
- European Federation of Pharmaceutical Industries and Associations (EFPIA) (2003), 'The Pharmaceutical Industry in Figures – Key Data 2003 Update', Brussels: IFPIA.

- European Generic Medicines Association (2000), Position paper, 'A proposal to include a development and testing provision for generic medicines in national and EU laws', Brussels: EFA, July.
- European Parliament (1999), *European Parliament Resolution on the Communication from the Commission to the Council and to the European Parliament: The EU Approach to the WTO Millennium Round*, COM(1999)331-C5-0155/1999-1999/2149(COS), document number: A5-0062/1999, 18 November.
- European Parliament (2001a), *Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use*, Official Journal of the European Communities, 28 November, L 311/67.
- European Parliament (2001b), *European Parliament Resolution on the WTO Fourth Ministerial Conference*, 25 October, document numbers: B5-091,0692 and 0693/2001.
- European Parliament, Committee on External Economic Relations (1996), *Report on the World Trade Organisation*, 14 October, document number: A4-0320/96.
- European Parliament, Committee on Legal Affairs and Citizens' Rights (1998), *Report on the Green Paper on the Community Patent and the Patent System in Europe: Promoting Innovation through Patents*, 28 October, Com(97)0314-C4-0342/97.
- European Parliament, Committee on Research Technological Development and Energy (1996), *Report and Resolution on the Prospects of European Science and Technology Policy in the 21st Century*, 28 November, document number: A4-0376/96.
- European Parliament, External Trade Committee on Industry, Research and Energy (1999), *Report on the Communication from the Commission to the Council and to the European Parliament: The EU Approach to the WTO Millennium Round*, COM(1999)331-C5-0155/1999-1999/2149(COS), document number: A5-0062/1999; PE 231.700/fin, 18 November.
- European Parliament and the Council of the European Union (1998), *Directive 98/44/EC of the European Parliament and of the Council of the European Union of July 6 July 1998 on the Legal Protection of Biological Inventions*, 6 July.
- European Union (1997), *Consolidated Version of the Treaty Establishing the European Community*, Luxembourg.
- European Union – General Affairs Council (2001), Extract from press release, 'Item WTO', 29 October, document number: SN/7301.
- Evans, P. and J. Walsh (1994), *The EIU guide to the New GATT*, London: The Economist Intelligence Unit.

- Evenson R. (1990), 'Intellectual property rights, R&D, inventions, technology purchase and piracy in economic development: an international comparative study', in R. Evenson and G. Ranis (eds), *Science and Technology: Lessons for Development Policy*, London: Intermediate Technology Publications, pp. 325–56.
- Faigen, N. (1993), 'The multinational threat in the generic market', *Scrip Magazine*, April, pp. 13–14.
- Feinberg, R.M. and D.J. Roussslang (1990), 'The economic effects of intellectual property rights infringements', *Journal of Business*, **63**, 79–90.
- Financial Times Survey (1999), *The World's Top Companies – Annual Review*, 28 January.
- Financial Times Survey (2000), *FT 500*, 4 May.
- Firn, D. (2001), 'Welcome for new gene patent rules', *Financial Times*, 8 January.
- Frankel, J. (1993), 'Selling to doctors in Europe', *Scrip Magazine*, June 1993, pp. 26–9.
- Freudenheim, M. (1998), 'The media business: influencing doctor's orders', *New York Times*, 17 November.
- Frieden A.J. (1991), 'Invested interests: the politics of national economic policies in a world of global finance', *International Organization*, **54**(4), Autumn, pp. 425–54.
- Frieden, A.J. and E.D. Lake (1995), *International Political Economy*, London: St. Martin's Press.
- Frieden A.J. and R. Rogowski (1996), 'The impact of the international economy on national policies: an analytical overview', in R. Keohane and H. Milner (eds), *Internationalization and Domestic Politics*, Cambridge: Cambridge University Press, pp. 25–47.
- Frischtak, C. (1990), 'The protection of intellectual property rights and industrial technology development in Brazil', in F.W. Rushing and C.G. Brown (eds), *Intellectual Property Rights in Science, Technology, and Economic Performance*, Boulder, San Francisco: Westview Press, pp. 61–98.
- Furniss, J. (1994), 'The profit control system in the UK', in E. Mossialos, C. Ranos and B. Able-Smith (eds), *Cost Containment, Pricing and Financing of Pharmaceuticals in the European Community – The Policy Maker's View*, London: LSE Health and Pharmetrica SA, pp. 311–20.
- Gadbaw, R.M. and T.J. Richards (1988), *Intellectual Property Rights: Global Consensus, Global Conflict*, Boulder: Westview Press.
- Gallardo, J., President – EFPIA (1998), *Millennium Round*, letter addressed to Sir Leon Brittan, Vice President European Commission, Brussels: 4 January.
- Gambardella, A. (1995), *Science and Innovation*, Cambridge: Cambridge University Press.

- GATT (1987), *Suggestion by the United States for Achieving the Negotiations Objective (IPRs)*, Geneva: 20 October, document number: MTN.GNG.NG11/W/14.
- GATT (1988), *Negotiating Group on Trade Related Aspects of Intellectual Property Rights Including Trade in Counterfeited Goods – Guidelines and Objectives Proposed by the European Community for the Negotiations on Trade Related Aspects of Intellectual Property Rights*, July, document number: MTN.GNG.NG11/W/26.
- GATT (1990), *Meeting of the Negotiating Group of 11, 12 and 14 December 1989*, Note by the Secretariat, 23 January, document number: MTN.GNG/NG11/17.
- GATT (1991), *Progress of Work in Negotiating Groups: Stock Taking*, Geneva: 7 November, document number MTN.TNC/W/89/Add.1.
- German Patent and Trade Mark Office (2000), 'Patent and trade mark office registered more than 94,000 patent applications in 1999 – inventiveness and innovativeness never more productive', 23 March.
- Geuze, M. Counsellor Intellectual Property Division, WTO (1999), 'Notifications, compliance, disputes and the in-built agenda', in: *Financial Times Conference – Intellectual Property and Global Trade: TRIPs and a New WTO Round*, London: FT, 30 September.
- Gilbert, R.J. and G.D. Newbery (1982), 'Preemptive patenting and the persistence of monopoly', *The American Economic Review*, 72(3), June, 514–26.
- Gilfillan, C. (1964), *Invention and the Patent System*, Study for the US Congress, Joint Economic Committee, 88th Congress, 2nd Session, Washington DC.
- Gilmartin, V.R., Chairman and Chief Executive Officer, Merck & Co Inc. (1998), 'The impact of economic and political factors on pharmaceutical innovation, CMR international annual lecture 1998', London: CMR International, 14 July.
- GlaxoSmithKline (2003), *2002 Annual Report*, London: GSK.
- Glaxo Wellcome (1998a), *Annual Review 1997*, London.
- Glaxo Wellcome (1998b), *Entering the Third Generation of Pharmaceutical R&D*, London.
- Gorlin, J. (1999), *An Analysis of the Pharmaceutical Related Provisions of the WTO TRIPs (Intellectual Property) Agreement*, London: Intellectual Property Institute.
- Gorlin, J. and S.C. Levy (1994), *Views of the Intellectual Property Committee on the Uruguay Round Intellectual Property (TRIPs) Agreement (March 16th Hearing) – Presented to the Committee on Finance, United States Senate*, Washington DC: IPC, 6 April.
- Gorlin, J. and S.C. Levy (1998), 'US Intellectual Property Committee Comments regarding US preparations for the World Trade Organisation's Meeting', Fourth Quarter 1999, addressed to Mr Frederick L. Montgomery,

- Chairman, Trade Policy Staff Committee, Office of the United States Trade Representative, Washington DC: IPC, 19 October.
- Gould, D.M. and W.C. Gruben (1995), 'The role of intellectual property rights in economic growth', *Journal of Development Economics*, **48**, 323–50.
- Grabowski, H. and J. Vernon (1986), 'Longer patents for lower imitation barriers: the 1984 Drug Act', *The American Economic Review*, **76**(2), May, 195–8.
- Grabowski, H. and J. Vernon (1990), 'A new look at the returns and risks to pharmaceutical R&D', *Management Science*, **36**(7), 804–21.
- Grabowski, H. and J. Vernon (1994), 'Returns to R&D on new drug introductions in the 1980's', *Journal of Health Economics*, **13**, 383–406.
- Greenwood, J. (1994a), *Representing Interests in the European Union: Sectors, Case Studies and Generalisations – Paper Prepared for the Panel on Organised Economic Interests and the European Union*, Chicago: 31 March–2 April.
- Greenwood, J. (1994b), *Representing Interests in the European Union: The Contribution of Case Study Methods*, Paper prepared for the presentation at the XVIth World Congress of the International Political Science Association, Berlin: 21–25 August.
- Greenwood, J. (1994c), 'Pharma and biotech: virtues and trends in EU lobbying', in M.P.C.P Van Schendelen and R.H. Pedler (eds), *Lobbying the European Union*, England: Dartmouth, pp. 183–98.
- Greenwood, J. (1997), *Representing Interests in the European Union*, New York: Macmillan Press.
- Greenwood J. and M. Aspinwall (eds) (1998), *Collective Action in the European Union*, New York: Routledge.
- Greenwood, J. and K. Ronit (1992), 'Established and emergent sectors: organised interests at the European level in the pharmaceutical industry and the new biotechnologies', in J. Greenwood, J. R. Grote and K. Ronit (eds), *Organised Interests and the European Community*, London: Sage, 69–98.
- Greenwood, J., J.R. Grote and K. Ronit (eds) (1992), *Organised Interests and the European Community*, London: Sage.
- Griffith, V. and M. Wrong (2000), 'Clinton and Blair press for free access to genetic codes', *Financial Times*, 15 March.
- Grossman, G.M. and C. Shapiro (1988), 'Counterfeit-Product Trade', *American Economic Review*, **78**(1), March, 59–75.
- Grundman, E.H. (1970), 'The economic arguments for patents and their validity for developing countries', *The Indian Economic Journal*, **19**(2), 193–207.
- Haagsma, A. (1990), 'A view from the European Community', in C.E. Walker and M.A. Bloomfield (eds), *Intellectual Property Rights and Capital*

- Formation in the Next Decade*, New York: University Press of America, pp. 65–76.
- Haas, M.P. (1990), *Saving the Mediterranean: The Politics of International Environmental Cooperation*, New York: Columbia University Press.
- Harris, G. (2001), 'Drug industry find its gaffes in Africa haunting it in the US', *Wall Street Journal Europe*, 23 April, pp. 1, 10.
- Harris, G. and R. Block (2001), 'Pharmaceutical firms withdraw South African HIV-drug case,' *The Wall Street Journal Europe*, 20 April, p. 3.
- Health Global Access Project and the Treatment Action Group (2001), 'Activists condemn the pharmaceutical industry's attempt to derail the implementation of South Africa's Medicines Act', New York: HealthGap, [http://www.healthgap.org/press\\_releases/01/013101\\_HGAP\\_GLAXO\\_Signon.html](http://www.healthgap.org/press_releases/01/013101_HGAP_GLAXO_Signon.html), 29 January.
- Hindley, B.V. (1971), *The Economic Theory of Patents, Copyrights, and Registered Industrial Designs: Background Study to the Report on Intellectual and Industrial Property*, Ottawa: Economic Council of Canada.
- t'Hoën, E. (2000), Médecins Sans Frontières, *Statement from Médecins Sans Frontières (MSF), Campaign for Access to Essential Medicines at the Health Issues Group – DG Trade*, Brussels: 26 June.
- Hogerzeil, H.V. (2000), 'The definition and selection process for an EDL', WHO: 27 October, document number: WHO/EDM/PAR.
- Hollon, F.M. (1999), 'Direct-to-consumer marketing of prescription drugs: creating consumer demand', *Journal of American Medical Association*, **27**(4), 27 January, pp. 382–4.
- Holmer, F.A. (1997), 'Direct-to-consumer prescription drug advertising builds bridge between patients and physicians' *Journal of American Medical Association (JAMA)*, **281**(4), January, 380–82.
- Holyoak, J. and P. Torremans (1995), *Intellectual Property Law*, London: Butterworths.
- Ignatius, D. (2000), 'Patents and lawyers pose the latest problem for cyberspace', *Herald Tribune*, 20 March, p. 8.
- IMF (1994), *International Trade Policies – The Uruguay Round and Beyond – Background Papers*, World Economic and Financial Surveys, vol.2, Washington, DC: IMF.
- IMS Health (1998), Press release, 'IMS reports pharmaceutical promotion rose 16% in 1997, Plymouth Meeting', 31 March.
- IMS Health (1999a), Press release, 'US pharmaceutical industry spent more than 5.8\$ billion on product promotion in 1998', London: 21 April.
- IMS Health (1999b), Press release, '1999 direct to consumer prescription drug advertising in US reaches \$1.5 billion for twelve months through March', London: 7 June.
- IMS Health (1999c), Press release, '1999 direct to consumer prescription drug advertising in US reaches \$905 through June', London: 12 October.



- IMS Health (2003a), 'Total US promotional spending by type, 2001', London.
- IMS Health (2003b), *World Review*, [www.imshealth.com/ims/portal/front/articleC/10%2C2777%2C1763%2C3665%2C41336931%2C00.html](http://www.imshealth.com/ims/portal/front/articleC/10%2C2777%2C1763%2C3665%2C41336931%2C00.html)
- Inside US Trade* (2001), *EU Withdraws TRIPs Compromise Proposal Opposed by Member States*, 26 October.
- Intellectual Property Committee (United States) (1991), 'GATT TRIPs negotiations: a status report', Washington DC: IPC, 23 October.
- Intellectual Property Committee (United States) (1994a), 'Principal outstanding issues in TRIPs', Washington DC: IPC, 24 November.
- Intellectual Property Committee (United States) (IPC) (1994b), 'Views of the Intellectual Property Committee on the Uruguay Round Intellectual Property (TRIPs) Agreement', Washington DC: IPC, April.
- International Chamber of Commerce (ICC) (1996), 'Intellectual property and international trade: a guide to the Uruguay Round TRIPs Agreement', Paris: ICC.
- International Chamber of Commerce, Counterfeiting Intelligence Bureau (ICC) (1997), *Counterfeiting Counterfeiting – A Guide to Protecting and Enforcing Intellectual Property Rights*, Paris: ICC.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (1989), *Intellectual Property and the Pharmaceutical Industry: The IFPMA View*, Geneva: IFPMA.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (1995a), *GATT TRIPs and the Pharmaceutical Industry: A Review*, Geneva: IFPMA.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (1995b), Press Information, 'New IFPMA Publication: GATT TRIPs and the Pharmaceutical Industry: A Review', April, Geneva: IFPMA.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (1997), *Intellectual Property: Patents and Pharmaceuticals – IFPMA Position*, Geneva: IFPMA, February.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (1998), *The Question of Patents*, Geneva: IFPMA.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (1999), IFPMA position paper, 'WTO Millennium Round', Geneva: IFPMA, 2 November.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2000a), 'IFPMA administration and objectives', Geneva: IFPMA website: [www.ifpma.org](http://www.ifpma.org).
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2000b), 'IFPMA member associations', Geneva: IFPMA website: [www.ifpma.org](http://www.ifpma.org).

- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2000c), 'Mission of the International Federation of Pharmaceutical Manufacturers Association', Geneva: IFPMA website: [www.ifpma.org](http://www.ifpma.org).
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2000d), 'Main areas of activities', Geneva: IFPMA website: [www.ifpma.org](http://www.ifpma.org).
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2000e), *Parallel Trade: A Recipe for Reducing Patients Access to Innovative and Quality Medicines*, Geneva: IFPMA.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2001a), 'TRIPs Council special session', Geneva: IFPMA, 21 September.
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2001b), Press release 'The research-based pharmaceutical industry agrees with the Doha WTO Ministers that intellectual property protection is vital to trade, access and innovation', Geneva: IFPMA, 14 November.
- International Generic Pharmaceutical Alliance (1998), 'Globalisation of pharmaceuticals – effects of trade agreements on intellectual property and public health', oral presentation by Greg Perry, IGPA Co-Director at the WHO in Geneva', Brussels: IGPA, 13 October.
- INTERPAT Update (1992), 'News – Patents and Trademarks: Developments in Industrial Property Rights', **21**, January, 14–17.
- INTERPAT (1998a), 'INTERPAT Statutes, as accepted by the General Assembly', 23 March.
- INTERPAT – General Assembly (1998b), 'INTERPAT Guidelines', 25 March.
- INTERPAT (1999), 'INTERPAT Work Groups, Paris Conference', 16–20 May.
- Jackson, J.H. (1997), *The World Trading System: Law and Policy of International Economic Relations*, 2nd edn, Cambridge, Massachusetts: MIT Press.
- Jackson, J.H. (2000), 'Dispute settlement and the WTO: emerging problems', in WTO Secretariat (ed.), *From GATT to the WTO: The Multilateral Trading System in the New Millennium*, Boston: Kluwer.
- Jordan, M. (2001), 'Brazil threatens to break patent on Aids', *The Wall Street Journal Europe*, 24 August.
- Kahn, A.E. (1940), 'Fundamental deficiencies of the American economic law', *The American Economic Review*, **XXX** (3), September, 475–591.
- Katz, J.M. (1973), *La Industria Farmaceutica Argentina, Estructuray Comportamiento*, Documento de Trabajo, Instituto Torcuato Di Tella, Buenos Aires, Argentina: Centro de Investigaciones Economicas, July.
- Kehoe, L. (1999), 'Amazon defends "one click" patent', *Financial Times*, 23 October.

- Kehoe, L. and R. Wolfe (1999), 'Intel denies conduct stifled competition', *Financial Times*, 2 March, p. 3.
- Keidanren (Japan), UNICE (Western Europe) and Intellectual Property Committee (USA) (1998), *Basic Framework of GATT Provisions on Intellectual Property: Statement of the Views of the European, Japanese and the United States Business Communities*, June.
- Keohane, R.O. and H.V. Milner (eds) (1996), *Internationalization and Domestic Politics*, Cambridge: Cambridge University Press.
- Kermani, F. (2002), 'Research and development for the 21st Century pharmaceutical industry', *Business Briefing: Pharmatech2002*, pp. 56–9.
- King, G., R.O. Keohane and S. Verba (1994), *Designing Social Inquiry*, New Jersey: Princeton University Press.
- Kinnock, G., Member of the European Parliament (2001), 'Drug companies should drop their case and save face', *Financial Times*, letters to the Editor, 9 March.
- Kitti, C. (1985), 'Patent life and the optimal timing of innovations', in G.S. Tolley, J.F. Oehmke and J.H. Hodge (eds), *The Economics of R&D Policy*, New York: Praeger, pp. 70–94.
- Koehler, S. (1997), *Germany: Drugs and Pharmaceuticals*, Industry Sector Analysis, Hamburg: Tradeport.
- Krasner, S. (1996), 'The Accomplishments of international political economy', in S.M. Smith, K. Booth and M. Zaleski (eds), *International Theory Positivism and Beyond*, Cambridge: Cambridge University Press.
- Krueger, O.A. (1974), 'The political economy of the rent-seeking society', *American Economic Review*, **64**(3), June, 291–302.
- Krugman, P.R. and M. Obstfeld (1997), *International Economics*, 4th edn, Reading, Mass.: Addison Wesley.
- Kuznets, S. (1962), 'Inventive activity: problems of definitions and measurement', in National Bureau of Economic Research (ed.) *The Rate and Direction of Inventive Activity: Economic and Social Factors*, Princeton, New Jersey: Princeton University Press, pp. 19–51.
- Labovitz, S. and R. Hagedorn (1971), *Introduction to Social Research*, New York: McGraw Hill.
- Ladas, P.S. (1975), *Patents, Trademarks, and Related Rights: National and International Protection*, vol.1, Cambridge, Massachusetts: Cambridge University Press.
- Lamy, P., European Commissioner for Trade (2001), 'Europe has listened, Europe has moved, and Europe is willing to go the extra mile', statement by Pascal Lamy at opening press conference, WTO Ministerial Meeting, Doha, 9 November 2001.
- Law, J. (1999), 'Preparing to advertise directly to consumers', *Scrip Magazine*, November 1999, pp. 6–7.

- Lele, U., W. Lesser and G. Horskotte-Wessler (1999), *Intellectual Property Rights and Agriculture*, Washington, DC: World Bank.
- Lemonick, M.D. and F. Golden (2000), 'Mapping the genome – the race is over', *Time Magazine*, **156**(1), 3 July, 73–8.
- Leschly, J., Chief Executive Officer, SmithKline Beecham (1997), 'Open discussion public procurement for healthcare', in European Federation of Pharmaceutical Industries and Associations (ed.), *Second Round Table 'Completing the Single Pharmaceutical Market'*, Frankfurt: IMS Health, 8 December.
- Levin, R.C., A.K. Klevorick, R.R. Nelson and S.G. Winter (1987), 'Appropriating the returns from industrial R&D', *Brookings Papers on Economic Activity*, **3**, 783–820.
- Lipsey, G.R. and N.P. Courant (1996), *Microeconomics*, 11th edn, New York: Harper Collins.
- Louis, M. and A. Regalado (2001), 'Ethics stand in the way of patents', *The Wall Street Journal Europe*, 21 August.
- Lunsford, J.R. (1974), 'Consumers and trademarks: the function of trademarks in the market place', *The Trademark Reporter*, **64**, p. 83.
- Luscombe, K.D., R.S. Walker, A.S. Griffiths and G.F. MacFarlane (1997), 'Worldwide pharmaceutical R&D expenditure: can the growth continue,' *International Journal of Pharmaceutical Medicine*, **11**, pp. 193–9.
- Macarthur, D. (1994), 'A foot in both camps: forays by research-based companies', *Scrip Magazine*, April, pp. 43–5.
- Machlup, F. (1958), *An Economic Review of the Patent System*, Study of the Subcommittee on Patents, Trademarks and Copyrights of the Committee on the Judiciary, United States Senate, 85th Congress, Second Session, Study No. 15, Washington DC: Committee on the Judiciary, Government Printing Office.
- Machlup, F. (1962a), *The Production and Distribution of Knowledge in the United States*, Princeton, New Jersey: Princeton University Press.
- Machlup, F. (1962b), 'The supply of inventions and inventors', in National Bureau of Economic Research (ed.), *The Rate and Direction of Inventive Activity: Economic and Social Factors*, Princeton, New Jersey: Princeton University Press, pp. 143–69.
- Mankiw, N.G. (1998), *Principles of Economics*, Fort Worth: Dryden Press.
- Mansfield, E. (1986), 'Patents and innovation: an empirical study', *Management Science*, February, pp. 173–81.
- Mansfield, E. (1994), *Intellectual Property Protection, Foreign Direct Investment and Technology Transfer*, International Finance Corporation, Discussion Paper No. 19, Washington DC: World Bank.

- Mansfield, E. and Jeong-Yeon Lee (1996), 'Intellectual Property Protection and US Foreign Direct Investment', *The Review of Economics and Statistics*, **LXXVIII**(2), May, 181–6.
- Mansfield, P.R. (1997), *How Does Pharmaceutical Company Promotion Affect Prescribing*, Action Programme on Essential Drugs, www.who.int/dap-icium, Thailand: WHO, April.
- Marshall, A. (1946), *Principles of Economics*, 8th edn, London: Macmillan.
- Maskus, K.E. (1990), 'Intellectual Property', in J. Schott (ed.), *Completing the Uruguay Round*, Washington, DC: Institute for International Economics, pp. 164–80.
- Maskus, K.E. and D.E. Konan (1994), 'Trade-Related Intellectual Property Rights: issues and exploratory results', in A.V. Deardorff and R.M. Stern (eds), *Analytical and Negotiating Issues in the Global Trading System*, Ann Arbor: The University of Michigan Press, pp. 401–54.
- Maskus, K.E. Penubarti, M. (1995), 'How trade-related are intellectual property rights?', *Journal of International Economics*, **39**, 227–48.
- Maskus, K.E. (1999), *Intellectual Property Issues for the New Round*, Washington DC: Institute for International Economics, 2 November.
- Maskus, K.E. (2000), *Intellectual Property Rights in the Global Economy*, Washington DC: Institute for International Economics.
- March, J.G. and J.P. Olsen (1989), *Rediscovery Institutions*, New York: Free Press.
- Mazey, S. and J. Richardson (1996), 'The logic of organisation – interest groups, in Jeremy Richardson (ed.), *European Union – Power and Policy Making*, London: Routledge, pp. 200–215.
- McCubbins, M.D. and T. Schwartz (1984), 'Congressional oversight overlooked: police patrols versus fire alarms', *American Journal of Political Science*, **2**, 165–79.
- McGirk, T. (1998), 'Dealing in DNA', *TIME Magazine*, **152**(2), 30 November.
- Médecins Sans Frontières (2001a), 'Help build the drop the case petition', MSF website: www.msf.org.
- Médecins Sans Frontières (2001b), 'Statement by MSF on TRIPs and affordable medicines – TRIPs Council session on access to medicines', Geneva: MSF, 18 September.
- Médecins Sans Frontières (2001c), 'Green light to put public health first at WTO Ministerial Conference in Doha', Joint Statement by MSF, Oxfam, Third World Network, Consumers Project on Technology and Consumers International, MSF, 14 November.
- Merck & Co. (2003), *2002 Annual Report*, Whitehouse Station, NJ: Merck.
- Michaels, A. (2000), 'FDA may block Merck patent plea', *Financial Times*, 13 July.

- Miller, C., Director of Programmes, Save the Children (2001), 'Pharmaceutical companies attack the world poorest', *Financial Times*, Letters to the Editor, 14 February.
- Milner, H.V. (1988), *Resisting Protectionism*, Princeton, New Jersey: Princeton University Press.
- Milner, H.V. (1995), 'Resisting the protectionist temptation', in J. Frieden and D. Lake (eds), *International Political Economy*, 3rd edn, London: St. Martin's Press, pp. 368–86.
- Milner, H.V. (1997), *Interests, Institutions, and Information*, Princeton, New Jersey: Princeton University Press.
- Mody, A. (1990), 'New international environment for intellectual property rights', in F.W. Rushing and C.G. Brown (eds), *Intellectual Property Rights in Science, Technology, and Economic Performance*, Boulder, San Francisco: Westview Press, pp. 203–39.
- Monroe, R. and A. Downs (eds) (1991), *The Economic Approach to Politics: A Critical Reassessment of the Theory of Rational Action*, New York: Harper Collins.
- Montagon, P. (1989a), 'India reluctant to swallow bitter pill of drugs patent reform – cheap medicines are the heart of an international dispute over intellectual property rights', *Financial Times*, 27 June.
- Montagon, P. (1989b), 'Patent law may be the key to Uruguay Round – the growing battle over intellectual property rights', *Financial Times*, 17 October.
- Montagon, P. and W. Dulforce (1998), 'Montreal trade talks: intellectual property talks stalled', *Financial Times*, 1 December.
- Mossialos, E., P. Kanavos and B. Abel-Smith (1994), 'The pharmaceutical sector in the European Union – an overview', in E. Mossialos, C. Ranos and B. Able-Smith (eds), *Cost Containment, Pricing and Financing of Pharmaceuticals in the European Community – The Policy Maker's View*, London: LSE Health and Pharmetrica SA, pp. 18–87.
- Mossinghoff, J.G. (1999), 'Overview of the Hatch–Waxman Act and its impact on the drug development process', *Food and Drug Law Journal*, **54**(2), 187–94.
- Mueller, D.C. (1991), *Public Choice II*, Cambridge, Mass.: Cambridge University Press.
- Nachmias, D. and C. Nachmias (1992), *Research Methods in the Social Sciences*, Tel-Aviv: Am Oved.
- Nagel, E. (1961), *The Structure of Science*, New York: Harcourt, Brace & World.
- Nelson R.R. (1959), 'The simple economics of basic scientific research', *Journal of Political Economy*, **LXVII**, June, 297–306.

- Nogués, J. (1990a), *Notes on Patents, Distortions and Development*, PPR Working Papers, Washington DC: World Bank, January.
- Nogués, J. (1990b), *Patents and Pharmaceutical Drugs – Understanding the Pressures on Developing Countries*, PPR Working Papers, Washington DC: World Bank, September.
- Nordhaus, W.D. (1969), *Invention, Growth and Welfare*, Cambridge, Massachusetts: MIT Press.
- North, D. (1990), *Institutions, Institutional Change and Economic Performance*, New York, Cambridge: Cambridge University Press.
- Novartis (1999), 'Launch of a Global Leader in Agribusiness – Features Stories', Basel: 2 December.
- Oatly, T. and R. Nabors (1998), 'Redistributive cooperation: market failure, wealth transfers and the Basle Accord', *International Organization*, **52**(1), Winter, 35–54.
- Oaxly, A. (1990), *The Challenge of Free Trade*, London: Harvester Wheatsheaf.
- OECD (1985), *The Pharmaceutical Industry – Trade Related Issues*, Paris: OECD.
- OECD (1987), *International Technology Licensing: Survey Results*, Paris: OECD, Mimeo, August.
- OECD (1989), *Economic Arguments for Protecting Intellectual Property Effectively*, Paris: OECD.
- OECD (1993), *Proposed Standard Practice for Surveys of Research and Experimental Development: Frascati Manual 1993*, Paris: OECD.
- OECD (1996a), *Services Statistics on International Transactions, 1990–1994*, Paris: OECD.
- OECD (1996b), *Intellectual Property, Technology Transfer and Genetic Resources – An OECD Survey of Current Practices and Policies*, Paris: OECD.
- OECD (1998), *Competition Policy and Intellectual Property Rights*, Paris: September, document number: DAF/CLP(98)18.
- OECD (2003), *Services Statistics on International Trade in Services 1992–2001*, Paris: OECD.
- Office of the Prime Minister, United Kingdom (2000), *Joint Statement by the Prime Minister Tony Blair and President Clinton on Human Genetic Research*, 14 March.
- Olson, M. (1965), *The Logic of Collective Action*, Cambridge, Massachusetts: Harvard University Press.
- Olson, M. (1982), *The Rise and Decline of Nations*, New Haven: Yale University Press.
- Otten, A. (1997), *The Implication of the TRIPs Agreement for the Protection of Pharmaceutical Inventions*, Geneva: WTO.

- Otten, A., Director of Intellectual Property and Investment Division WTO (1998), 'Implications of the TRIPs Agreement and prospects for its further development', *Journal of International Economic Law*, **1**(4), 523–36.
- Oxfam (2001a), *Patent Injustice: How World Trade Rules Threaten the Health of Poor People*, London: Oxfam.
- Oxfam (2001b), *Fatal Side Effects: Medicine Patents under the Microscope*, London: Oxfam.
- Penrose, E. (1951), *The Economics of the International Patent System*, Baltimore: Johns Hopkins Press.
- Penrose, E. (1973), 'International patenting and less-developed countries', *The Economic Journal*, **83**, September, 765–85.
- Penrose, E. and F. Machlup (1950), 'The patent controversy in the nineteenth century', *Journal of Economic History*, **X**(1), May, 1–29.
- Peny, J.M. (2003), 'How bright is the future for generics', *Scrip Magazine*, March, pp. 13–17.
- Pfizer (1998), *1997 Annual Report*, New York: Pfizer.
- Pfizer (1999), *1998 Annual Report*, New York: Pfizer.
- Pfizer (2003), *2002 Annual Report*, New York: Pfizer.
- Pharmaceutical Researchers and Manufacturers of America (PhRMA) (1997), 'A Critique of WHO DAP Series Number 7 – Globalisation and Access to Drugs: Implication of the TRIPs Agreement', Washington DC: PhRMA.
- Pharmaceutical Researchers and Manufacturers Association of America (PhRMA) (1998), *Industry Profile 1998*, Washington DC: PhRMA.
- Pharmaceutical Researchers and Manufacturers Association of America (PhRMA) (1999), *Industry Profile 1999*, Washington DC: PhRMA.
- Pharmaceutical Researchers and Manufacturers Association of America (PhRMA) (2003), *Industry Profile 2003*, Washington DC: PhRMA.
- Pharmaceutical Researchers and Manufacturers Association of America (PhRMA) (2001), 'WTO Doha Declaration reaffirms value of intellectual property protection', Washington DC: PhRMA, 14 November.
- Phillips, J. and A. Firth (1995), *Introduction to Intellectual Property Law*, London: Butterworths.
- Pigou, C.A. (1924), *The Economics of Welfare*, 4th edn London: Macmillan.
- Pilling D. (1998), 'Zeneca and Astra Set to Merge', *Financial Times*, 9 December, p. 1.
- Pilling D. (1999a), 'Losing the drug war', *Financial Times*, 13 April.
- Pilling, D. (1999b), 'Scientists combine in bid to crack gene code', *Financial Times*, 15 April.
- Pilling D. (2001a), 'Rivals in race to cut prices of Africa's Aids drugs', *Financial Times*, 14 March.
- Pilling, D. (2001b), 'WHO backs South African law on drugs patents', *Financial Times*, 17 March, p. 2.



- Pilling D. (2001c), 'Third world and drugs groups remain wary of each other', *Financial Times*, 10 July.
- Plant, A. (1934), 'Economic theory concerning patents', *Economica – New Series*, **I**, 30–51.
- Polanyi, M. (1944), 'Patent reform', *Review of Economic Studies*, **11**, 61–76
- Popper, K. (1968), *The Logic of Scientific Inquiry*, New York: Harper and Row.
- Primo-Braga, C. (1989), 'The economics of intellectual property rights and the GATT: A view from the South', *Vanderbilt Journal of Transnational Law*, **22**(2), 243–64.
- Primo-Braga, C. (1990a), 'The developing countries case for and against intellectual property protection', in W. E. Siebeck (ed.), *Strengthening Protection of Intellectual Property in Developing Countries*, World Bank Discussion Papers No. 112, Washington, DC: World Bank, pp. 69–87.
- Primo-Braga, C. (1990b), 'Sectoral Issues I', in W. E. Siebeck (ed.), *Strengthening Protection of Intellectual Property in Developing Countries*, World Bank Discussion Papers No. 112, Washington, DC: World Bank, pp. 47–58.
- Primo-Braga, C. (1990c), 'Guidance from economic theory', in: Siebeck (ed.), *Strengthening Protection of Intellectual Property in Developing Countries*, World Bank Discussion Papers No. 112, Washington, DC: World Bank, pp. 17–32.
- Primo-Braga, C. and C. Fink (1998), 'Reforming intellectual property rights regimes: challenges for developing countries', *Journal of International Economic Law*, **1**(4), 537–54.
- Reekie, W. D. and M. H. Weber (1979), *Profits, Politics and Drugs*, London: Macmillan.
- Reichman, H. J. (1998), 'Securing compliance with the TRIPs Agreement after US v India', *Journal of International Economic Law*, **1**(4), 581–601
- Republic of South Africa (1997), *Medicines and Related Substances Control Amendment Act No. 90*, 23 November.
- Republic of South Africa Department of Health (2001a), Press release, 'South African Medicines Act postponed', Pretoria: 6 March.
- Republic of South Africa Department of Health (2001b), Press release, 'Meeting of SADC Health Ministers with pharmaceutical companies', Pretoria: 8 June.
- Rice, R. (1990), 'Patent differences holding up deal to protect ideas', *Financial Times*, 13 November.
- Richardson J. (ed.) (1996), *European Union – Power and Policy Making*, London: Routledge.
- Richardson, P., General Patent Council and Pfizer (1999), 'Patent Standards Lessons from Commercial Experience in the US and the EU', in: Financial

- Times Conference 'Intellectual property and global trade: TRIPs and a new WTO Round', London: FT, 30 September.
- Riker, W. H. (1962), *The Theory of Political Coalitions*, New Haven: Yale University Press.
- Roberts, D., Director Corporate Intellectual Property, SmithKline Beecham (1999), 'Protection of test data and market exclusivity', in: Financial Times Conference 'Intellectual property and global trade: TRIPs and a new WTO round', London: FT, 30 September.
- Robinson, J. (1956), *The Accumulation of Capital*, London: Macmillan.
- Roche (2001), Media release, 'Roche and the Brazilian Ministry of Health reach an agreement for supply of HIV drug Viracept', Basel: 31 August.
- Rogowski, R. (1989), *Commerce and Coalitions*, Princeton, New Jersey: Princeton University Press.
- Rozek, R. P. (1990), 'Protection of Intellectual Property Rights – Research and Development Decisions and Economic Growth', in F. W. Rushing and C. G. Brown (eds), *Intellectual Property Rights In Science, Technology, and Economic Performance*, Boulder, US: Westview Press, pp. 31–46.
- Ryan, M. P. (1998), *Knowledge Diplomacy: Global Competition and the Politics of Intellectual Property*, Washington DC: Brookings Institute Press.
- Sachs, J. (1999), 'Helping the world's poorest', London: *The Economist*, 14–20 August, pp. 17–20.
- Sally, R. (1994), 'Multinational enterprises, political economy and institutional theory: domestic embeddedness in the context of internationalisation,' *Review of International Political Economy*, 1(1) Spring, 161–92.
- Sally, R. (1995), *States and Firms*, London: Routledge.
- Sanders, B. S. (1962), 'Some difficulties in measuring inventive activity', in National Bureau of Economic Research (ed.), *The Rate and Direction of Inventive Activity: Economic and Social Factors*, Princeton, New Jersey: Princeton University Press, pp. 53–90.
- Schechter, F. I. (1925), *The Historical Foundations of the Law Relating to Trade-marks*, New York: Columbia University Press.
- Scherer, F. M. (1970), *Industrial Market Structure and Economic Performance*, Chicago: Rand McNally.
- Scherer, F. M. (1972), 'Nordhaus' theory of optimal patent life: a geometric reinterpretation', *American Economic Review*, 62, June, 422–7.
- Schott, J. J. (ed) (1994), *The Uruguay Round – An Assessment*, Washington, DC: Institute for International Economics, November.
- Schumann, G. (1990), 'Economic development and intellectual property protection in Southeast Asia', in F. W. Rushing and C. G. Brown (eds), *Intellectual Property Rights in Science, Technology, and Economic Performance*, Boulder, San Francisco, Westview Press, pp. 157–202.

- Schumer, C. E. (2001), 'Press release, 'New Cipro source could dramatically increase supply', Washington: Office of Senator Charles Schumer, 16 October.
- Scrip (1997), *EFPIA To Allow Company Membership*, No. 2216, 21 March.
- Scrip (1998), *DTC Promotion gains ground in the US*, No. 2392, p. 14.
- Scrip (1999), *UK Companies Push DTC Ads Rules*, No. 2472, 15 September, p. 6.
- Scrip Magazine (1993), *Teva – a Small Company with Big Ideas*, April, pp. 40–41.
- Scrip Magazine (1994), *Research Alliances in 1993*, January, pp. 36–7.
- Scrip Magazine (1999), *Viagra Steals the Show*, January, pp. 54–6.
- Scrip Magazine (2000a), *From Penicillin to Viagra – A Century of Achievements*, January, pp. 37–40.
- Scrip Magazine (2000b), *Healthy Growth for World Pharma Sales*, February, pp. 34–6.
- Scrip Magazine (2000c), *Merck Holds Top Position for the Last Time?*, February, pp. 44–5.
- Scrip Magazine (2000d), *Managing Innovation Gap with M&As*, February, pp. 47–9.
- Scrip Magazine (2003a), *Sales Growth Start to Slow*, February, pp. 32–3.
- Scrip Magazine (2003b), *The Rise and Rise of Pfizer*, February, pp. 40–41.
- Seale, C. (1998), 'Qualitative interviewing', in C. Seale (ed.), *Researching Society and Culture*, London: Sage, pp. 202–16.
- Selke, G. (1994), 'Reference Price System in the European Community', in E. Mossialos, C. Ranos and B. Able-Smith (eds), *Cost Containment, Pricing and Financing of Pharmaceuticals in the European Community – The Policy Maker's View*, London: LSE Health and Pharmetrica SA, pp. 147–60.
- Sharma, A. and M. Heywood (2001), Head of Campaigners, Action for Southern Africa and Deputy Chairperson, Treatment Action Campaign, 'Drug patents and the fights against HIV', *Financial Times*, letters to the Editor, 5 March.
- Shechter, Y. (1998), *Interests, Strategies, and Institutions: Lobbying in the Pharmaceutical Industry of the European Union*, London: London School of Economics.
- Sherwood, M. R. (1990a), *Intellectual Property and Economic Development*, Boulder, San Francisco: Westview Press.
- Sherwood, M. R. (1990b), 'A microeconomic view of intellectual property protection in Brazilian Development', in F. W. Rushing and C. G. Brown (eds), *Intellectual Property Rights in Science Technology, and Economic Performance*, Boulder, San Francisco: Westview Press, pp. 113–32.
- Shively, P. W. (1997), *The Craft of Political Research*, 4th edn, Upper Saddle River, NJ: Prentice Hall.

- Siebeck, W. E. (ed.) (1990), *Strengthening Protection of Intellectual Property in Developing Countries: A Survey of the Literature*, World Bank Discussion Papers No. 112, Washington, DC: World Bank.
- Silverman, M. and P. R. Lee (1974), *Pills, Profits and Politics*, Berkeley: University of California Press.
- SmithKline Beecham (1997), *Annual Report and Accounts 1997*, Middlesex: SB.
- SmithKline Beecham (1998), *Communiqué – WorldWide Managers' Magazine*, **9**(3), Middlesex: SB, Autumn.
- SmithKline Beecham (1999), *Communiqué – WorldWide Managers' Magazine*, **10**(3), Middlesex: SB, Summer.
- Stewart, P. T. (ed.) (1993a), *GATT Uruguay Round – A Negotiating History (1986–1992)*, vol. 2 – Commentary, Boston: Kluwer.
- Stewart, P. T. (ed.) (1993b), *GATT Uruguay Round – A Negotiating History (1986–1992)*, vol. 3, Boston: Kluwer.
- Stiglitz, E. J. (1999), 'Knowledge as global public good', in I. Kaul, I. Grunberg and M. A. Stern (eds), *Global Public Goods: International Cooperation in the 21st Century*, New York: Oxford University Press, pp. 308–25.
- Strange, S. (1997), *States and Markets*, 2nd edn, London: Pinter.
- Subramanian, A. (1990), 'TRIPS and the paradigm of the GATT: a tropical temperate view', *World Economy*, **13**(4), 509–21.
- Subramanian, A. (1995), 'Putting some numbers on the TRIPS pharmaceutical debate', *International Journal of Technology Management*, **10**(2/3), 252–3.
- Subramanian, A. and D. Hartridge (1989), 'Intellectual property rights: the issues in GATT', *Vanderbilt Journal of Transnational Law*, **22**(4), 893–910.
- Sykes, R., Chairman, GlaxoWellcome (2000), 'Advancing the world trade debate: beyond Seattle', in: *Commonwealth Trade Congress: The Opportunity for Business to Change the World Trade Debate*, London: 30–31 May.
- Taussig, W. F. (1915), *Inventors and Money Makers*, New York: Macmillan.
- Toedtman, J. (2001), 'Amid security fears, WTO talks begin', *Newsday.Com*, 9 November.
- Trans Atlantic Business Dialogue (TABD) (1997), 'Issue briefings for the Rome Conference', TABD, 6–7 November.
- Trans Atlantic Business Dialogue (TABD) (1998a), 'Scorecard of issues for intellectual property issues group', TABD, June.
- Trans Atlantic Business Dialogue (TABD) (1998b), 'Charlotte Statement of conclusions', Charlotte, North Carolina: TABD, 5–7 November.
- Trans Atlantic Business Dialogue (TABD) (1998c), 'Annex to the October 1997 action plan of the intellectual property issues group', Charlotte, North Carolina: TABD, November.

- Trans Atlantic Business Dialogue (TABD) (1999), 'Mid Year report – technical annex', Washington, DC: TABD, 10 May.
- Trans Atlantic Business Dialogue (TABD) (2000a), 'TABD Working Group structure', TABD website: [www.tabd.org](http://www.tabd.org).
- Trans Atlantic Business Dialogue (TABD) (2000b), 'TABD 2000 issue contacts', TABD website: [www.tabd.org](http://www.tabd.org).
- Trans Atlantic Consumer Dialogue (TACD) (1999), 'Pharmaceuticals', April, document number: Health-1-99.
- Trebilcock, M.J. and R. Howse (1995), (eds), *The Regulation of International Trade*, New York: Routledge.
- Tsoukalis, L. (1997), *The New European Economy Revisited*, Oxford: Oxford University Press.
- UNAIDS (2000a), *South Africa – Epidemiological Fact Sheet on HIV/AIDS and Sexually Transmitted Infections*, Geneva: UNAIDS.
- UNAIDS (2000b), *Report on the Global HIV/AIDS Epidemic*, Geneva: UNAIDS, June.
- United Industrial and Employers Confederation of Europe (UNICE) (1990), 'UNICE initial comments on the draft final Act of the Uruguay Round', Brussels: 10 January.
- United Industrial and Employers Confederation of Europe (UNICE) (1991), 'Draft UNICE position paper: GATT and intellectual property – chairman's text on TRIPs of 23 November 1990: the exhaustion issue (Article 6 of the Chairman text)', Brussels: 2 May.
- United Industrial and Employers Confederation of Europe (UNICE) (1997), 'Position paper, 'TRIPs and the Environment'', Brussels: 16 September.
- United Industrial and Employers Confederation of Europe (UNICE) and US Intellectual Property Committee (IPC) (1998), 'IPC–UNICE Meetings in Geneva and Brussels, 19–21 October: principal results and conclusions', London: 13 November.
- United Industrial and Employers Confederation of Europe (UNICE) (1999), *UNICE and the WTO Millennium Round*, Brussels: UNICE, September.
- United Industrial and Employers Confederation of Europe (UNICE) (2000a), 'UNICE's 10 priorities', Brussels: UNICE website: [www.unice.org](http://www.unice.org).
- United Industrial and Employers Confederation of Europe (UNICE) (2000b), 'Company affairs', Brussels: UNICE website: [www.unice.org](http://www.unice.org).
- United Industrial and Employers Confederation of Europe (UNICE) (2000c), *Working Groups*, Brussels: UNICE website: [www.unice.org](http://www.unice.org).
- United Industrial and Employers Confederation of Europe (UNICE) (2000d), 'Intellectual Property Rights – compendium of UNICE position papers', Brussels: UNICE, January.
- United Industrial and Employers Confederation of Europe (UNICE) (2000e), 'UNICE position paper on TRIPs and the environment', 16 September 1997',

in *Intellectual Property Rights – Compendium of UNICE Position Papers*, Brussels: UNICE, January.

United Industrial and Employers Confederation of Europe (UNICE) (2000f), ‘UNICE Position Paper on TRIPs implementation in the context of a possible millennium round – 13 November 1998’, in *Intellectual Property Rights – Compendium of UNICE Position Papers*, Brussels: UNICE, January.

United Industrial and Employers Confederation of Europe (UNICE) (2000g), ‘UNICE Comments on Exhaustion of trademarks and other intellectual property rights – 21 April 1999’, in *Intellectual Property Rights – Compendium of UNICE Position Papers*, Brussels: UNICE, January.

United Industrial and Employers Confederation of Europe (UNICE) (2000h), ‘UNICE Comments on TRIPs in the context of the Millennium Round – 28 June 1999’, in *Intellectual Property Rights – Compendium of UNICE Position Papers*, Brussels: UNICE, January.

United Nations (1992), *Convention on Biological Diversity*, Rio de Janeiro: 5 June.

United Nations Conference on Trade and Development (UNCTAD) (1975a), *The Role of the Patent System in the Transfer of Technology to Developing Countries*, New York: UNCTAD.

United Nations Conference on Trade and Development (UNCTAD) (1975b), *Major Issues in the Transfer of Technologies to Developing Countries – A Case Study of the Pharmaceutical Industry*, Geneva: UNCTAD.

United Nations Conference on Trade and Development (UNCTAD) (1979), *The Role of Trade Marks in Developing Countries*, New York: UNCTAD.

United Nations Conference on Trade and Development (UNCTAD) (1981), *Examination of the Economic, Commercial and Development Aspects of Industrial Property in the Transfer of Technology to Developing Countries: Trade Marks and Generic Names of Pharmaceuticals and Consumer Protection*, New York: UNCTAD.

United Nations Conference on Trade and Development (UNCTAD) (1996), *The TRIPs Agreement and Developing Countries*, New York: UNCTAD.

United Nations Conference on Trade and Development (UNCTAD) (1997), *World Investment Report 1997*, New York: UNCTAD.

United Nations Conference on Trade and Development (UNCTAD) (1999), *The Least Developed Countries 1998 Report*, New York: UNCTAD.

United Nations Department of Economic and Social Development (1993), *Intellectual Property Rights and Foreign Direct Investment*, New York: United Nations.

United Nations Food and Agriculture Programme (1983), *International Undertaking on Plant Genetic Resources, Resolution 8/83*, Rome.

- United States Court of Appeals for the Federal Circuit (1984), *Roche Products, Inc. v. Bolar Pharmaceutical*, decision number. 733 F.2d 858; Cert. Denied 221 USPQ 937; 469 US 856.
- United States Department of Health and Human Services (2001), Press release, 'HHS, Bayer agree to Cipro purchase', 24 October.
- United States Food and Drug Administration (1997), *Federal Food, Drug and Cosmetic Act*, Chapter 5 – Drugs and Devices, Section 505 (355) (D), Washington: FDA, <http://www.fda.gov/opacom/laws/fdcact/fdcact5a.htm>
- United States Food and Drug Administration (2003), *Electronic Orange Book*, [www.fda.gov/cder/ob/](http://www.fda.gov/cder/ob/)
- United States Information Agency (1995), 'Special 301 Trade Law – A USIA fact sheet', April.
- United States Information Agency (1999), 'Recommendation for evaluation of implementation pursuant to Paragraph 8 of the Geneva ministerial declaration – Communication from the United States', USIA.
- United States International Trade Commission (ITC) (1998), *Foreign Protection of Intellectual Rights and the Effects on US Industry and Trade*, Report to the United States Trade Representative Washington, DC: ITC, publication number:.. 2065.
- United States International Trade Commission (1999), *Review of the Global Competitiveness in the Pharmaceutical Industry*, Staff Research 25, Office of Industries US ITC, Washington, DC : ITC, April, publication number 3172.
- United States Mission to the European Union (2001), 'USTR Zoellick on WTO negotiations, security concerns', Brussels: 14 October.
- United States President's Commission on Industrial Competitiveness (1985), *Preserving America's Industrial Competitiveness: A Special Report on the Protection of Intellectual Property Rights*, Washington DC.
- United States (International) Trade Representative (1987), *US Framework Proposal to GATT Concerning Intellectual Property Rights*, BNA, 4 November, p. 1372.
- United States (International) Trade Representative (1989), *Framework Agreements Adopted April 8, 1989 at Midterm Review of Uruguay Round Negotiations Under General Agreement of Tariffs and Trade in Geneva*, BNA, 12 April, pp. 469, 471.
- United States Trade Representative (USTR) (1998a), *Reports Issued by the Office of the United States Trade Representative and Related Entities – Section 301 Table of Cases – Korea Intellectual Property Rights (301–52)*, Washington DC: USTR 4 June.
- United States Trade Representative (USTR) (1998b), *Reports Issued by the Office of the United States Trade Representative and Related Entities –*

- Section 301 Table of Cases – Korea Intellectual Property Rights – Brazil Pharmaceuticals (301–61)*, Washington DC: USTR, 4 June .
- United States Trade Representative (USTR) (1998c), *1999 Trade Policy Agenda and 1998 Annual Report*, Washington DC: USTR.
- United States Trade Representative (USTR) (2001a), ‘USTR on Trade Related Intellectual Property – background press conference: Fourth World Trade Organisation Ministerial Doha Qatar’, Washington DC: USTR, 12 November.
- United States Trade Representative (USTR) (2001b), ‘USTR fact sheet summarising results from WTO Doha meeting’, Washington DC: USTR, 14 November.
- Urry, M. (2000), ‘AstraZeneca figures fail to impress’, *Financial Times*, 25 February, p. 21.
- Vaitsos, C.V. (1971), *Transferencia de recursos y preservación de rentals monopolísticas, Revisita de Planeación Desarrollo*, Bogota, Colombia: July, pp. 56–7.
- Vaitsos, C. (1972), ‘Patents revisited: their function in developing countries’, *Journal of Development Studies*, 9(1), October, 71–98.
- Vandoren, P. (1999), Director of Unit DGI/D/3, European Commission, ‘Should intellectual property feature in the New Round? Intellectual property and the WTO, the EU perspective’, in *Financial Times Conference – Intellectual Property and Global Trade: TRIPs and a New WTO Round*, London: FT, 30 September.
- Verband Forschender Arzneimittelhersteller (VFA) (1997), *Insights 96: Annual Report of the German Association of Research Based Pharmaceutical Companies*, Bonn: VFA.
- Verband Forschender Arzneimittelhersteller (VFA) (1999a), *Insights 98: Annual Report of the German Association of Research Based Pharmaceutical Companies*, Bonn: VFA.
- Verband Forschender Arzneimittelhersteller (VFA) (1999b), ‘Positionspapier des Verbandes Forschender Arzneimittelhersteller zur WTO Millennium-Runde’, Bonn: VFA, November.
- Verband Forschender Arzneimittelhersteller (VFA) (1999c), *Statistics 99 – The Pharmaceutical Industry in Germany*, Berlin: VFA, June.
- Verband Forschender Arzneimittelhersteller (VFA) (2000a), *Insights 99: Annual Report of the German Association of Research Based Pharmaceutical Companies*, Berlin: VFA, June.
- Verband Forschender Arzneimittelhersteller (VFA) (2000b), ‘Pharmaceutical Exports and Imports in Europe, Japan and the USA (1996\1997)’, Germany: VFA.
- Verband Forschender Arzneimittelhersteller (VFA) (2002), *Statistics 2002 – The Pharmaceutical Industry in Germany*, Berlin: VFA.



- Vernon, R. (1957), *The International Patent System and Foreign Policy*, Study of the Subcommittee on Patents, Trademarks and Copyrights of the Committee on the Judiciary, United States Senate, 85th Congress, Second Session, Study No. 5, Washington DC: Committee on the Judiciary, Government Printing Office.
- Vernon, R. (1990), 'Trade and technology in the developing countries', in R. Evenson and G. Ranis (eds), *Science and Technology*, London: International Technology Publications, pp. 255–70.
- Waldmeir, P. (2001), 'Court rules on Napstar case today', *Financial Times*, 12 February.
- Weaver, W. and B. Rockman (1993), 'Assessing the effect of institutions', in R.K. Weaver and B.A. Rockman (eds), *Do Institutions Matter? Government Capabilities in the United States and Abroad*, Washington DC: The Brookings Institution, pp. 1–40.
- Weiler H.H.J. (2001), *The EU, the WTO and the NAFTA*, Oxford: Oxford University Press.
- Weiss, F. (1990), 'TRIPS in search of an itinerary: Trade Related Intellectual Property Rights and the Uruguay Round negotiations', in G. Sacerdoti (ed.), *Liberalization of Services and Intellectual Property in the Uruguay Round*, Fribourg, Switzerland: University Press, pp. 97–114.
- WHO (1997), *Globalization and Access to Drugs: Implications of the WTO/TRIPs Agreement*, Health Economics and Drugs – DAP series No. 7, Geneva: WHO, November.
- WHO – Department of Essential Drugs and Medicines Policy (2000a), *Essential Drugs in Brief*, Issue.1, 1 June.
- WHO – Department of Essential Drugs and Medicines Policy (2000b), *Essential Drugs in Brief*, Issue No. 2, 1 September.
- WHO – Department of Essential Drugs and Medicines Policy (2000c), *WHO Model List of Essential Drugs(EDL) 10th Edition by Drug Name*, Geneva: 1 June.
- WHO – Department of Essential Drugs and Medicines Policy (2001), *The Rationale of Essential Drugs*, Geneva: 4 July.
- Wieczorek-Zeul, H., German Federal Minister for Economic Cooperation and Development (1999), Opening Speech at the Global Development Network 1999 Conference, Bonn: 5 December.
- Williams F. (2001a), 'Experts tackle trademarks in cyberspace', *Financial Times*, 31 January.
- Williams F. (2001b), 'Stage set for clash at WTO meeting over drug patents', *Financial Times*, 25 October.
- Williams F. (2001c), 'Declaration on patent rules cheers developing countries', *Financial Times*, 15 November, p. 12.

- Williams, F. and G. De Jonquières (2001), 'Deal close on medicines and patents', *Financial Times*, 13 November, p. 17.
- Winestock, G. (2001), 'US negotiations with Cipro renew AIDS drug debate', *The Wall Street Journal Europe*, 26 October.
- Winters, A. (1990), 'The road to Uruguay', *The Economic Journal*, **100**(403), December, pp. 1288–303.
- WIPO-UNESCO (1985), *Model Provisions for National Laws for the Protection of Folklore Against Illicit Exploitation and Other Prejudicial Actions*, Geneva.
- WIPO (1998a), *Industrial Property Statistics 1996 – Publication B*, Geneva: [www.wipo.org](http://www.wipo.org).
- WIPO (1998b), *Round Table on Intellectual Property, Indigenous Peoples and Local Peoples, July 23 and 24, 1998, Document Presented by Mr. Antonio Jacanimijoy, Coordinating Body for the Indigenous Peoples' Organisations of the Amazon Basin (COICA)*, Quito, Geneva: 15 July, document number: WIPO/INDIP/RT/98/4E.
- WIPO (1999), *General Information*, Geneva: WIPO.
- WIPO (2000), *Intellectual Property Needs and Expectations of Traditional Knowledge Holders – World Intellectual Property (WIPO) Draft Report on Fact-Finding Missions on Intellectual Property and Traditional Knowledge (1998–1999)*, Geneva: 3 July.
- WIPO (2002), *Industrial Property Statistics 2000 – Publication B*, Geneva: [www.wipo.org](http://www.wipo.org).
- WIPO – International Bureau (1999), *Round Table on Intellectual Property and Traditional Knowledge – 1 and 2 November 1999 – Protection of Traditional Knowledge: A Global Intellectual Property Issue*, Geneva: WIPO, 22 October, document number: WIPO/IPTK/RT/99/2.
- WIPO – International Bureau (2000), *Round Table on Intellectual Property and Traditional Knowledge – November 1 and 2 1999*, Geneva: WIPO, 4 May, document number: WIPO/IPTK/RT/99/7.
- WIPO Secretariat (2001), *Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore – First Session, Geneva, April 30 to May 3, 2001*, 16 March, document number: WIPO/GRTKF/IC/1/3.
- Woolcock, S. (2000), 'European trade policy – global pressures and domestic constraints', H. Wallace and W. Wallace (eds) *Policy Making in the European Union*, 4th edn, Oxford: Oxford University Press, pp. 401–27.
- World Bank Bangladesh (1998), 'Economic trends and policy agenda', Dhaka: World Bank, May.
- WTO Annex 2, *Understanding on Rules and Procedures Governing the Settlement of Disputes*. Meir Perez Pugatch - 9781843767640

- WTO (1998), *Trading into the Future – Introduction to the WTO*, 2nd edn, Geneva: February.
- WTO – Appellate Body (1997), *India – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Report of the Appellate Body*, Geneva: 19 December, document number: WT/DS50/AB/R.
- WTO – Council for TRIPs (1996), *Annual Report (1996) of the Council for TRIPs*, Geneva.
- WTO – Council for TRIPs (1997), *Annual Report (1997) of the Council for TRIPs*, Geneva.
- WTO – Council for TRIPs (1998a), *Annual Report (1998) of the Council for TRIPs*, Geneva.
- WTO – Council for TRIPs (1998b), *Technical Cooperation Activities: Information From Other Intergovernmental Activities*, Geneva: WTO, November.
- WTO – Council for TRIPs (2001a), *Ministerial Declaration on the TRIPs Agreement and Public Health – Proposal by the African Group, Bangladesh, Barbados, Bolivia, Brazil, Cuba, Dominican Republic, Ecuador, Haiti, Honduras, India, Indonesia, Jamaica, Pakistan, Paraguay, Philippines, Peru, Sri Lanka, Thailand and Venezuela*, Geneva: 4 October, document number: IP/C/W/312.
- WTO – Council for TRIPs (2001b), *Preambular Language for Ministerial Declaration – Contribution from Australia, Canada, Japan, Switzerland and the United States*, Geneva: 4 October, document number: IP/C/W/313.
- WTO – Dispute Settlement Body (1996a), *Pakistan – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Request for Consultations by the United States*, Geneva: 6 May, document number: WT/DS36/1.
- WTO – Dispute Settlement Body (1996b), *Pakistan – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Request to Join Consultation: Communication from the European Communities*, Geneva: 28 May, document number: WT/DS36/2.
- WTO – Dispute Settlement Body (1996c), *Pakistan – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Request for the Establishment of a Panel by the United States*, Geneva: 4 July, document number: WT/DS36/3.
- WTO – Dispute Settlement Body (1997a), *Pakistan – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Notification of a Mutually-Agreed Solution*, Geneva: 7 March, document number: WT/DS36/4.
- WTO – Dispute Settlement Body (1997b), *India – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Request for Consultations by the European Communities*, Geneva: 6 May, document number: WT/DS79/1.

- WTO – Dispute Settlement Body (1997c), *India – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Report of the Panel*, 5 September, document number: WT/DS50/R.
- WTO – Dispute Settlement Body (1997d), *India – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Request for the Establishment of a Panel by the EC*, Geneva: 15 September, document number: WT/DS79/2.
- WTO – Dispute Settlement Body (1997e), *India – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Notification of an Appeal by India under paragraph 4 of Article 16 of the Understanding on Rules and Procedures Governing the Settlement of Disputes*, Geneva: 16 October, document number: WT/DS50/6.
- WTO – Dispute Settlement Body (1998a), *Minutes of Meeting held in the Centre William Rappard on 16 January 1998*, Geneva: 18 February, document number: WT/DSB/M/40.
- WTO – Dispute Settlement Body (1998b), *Minutes of Meeting held in the Centre William Rappard on 22 April 1998*, Geneva: 10 June, document number: WT/DSB/M/45.
- WTO – Dispute Settlement Body (1998c), *India – Patent Protection for Pharmaceutical and Agricultural Chemical Products: Complaint by the European Communities and their Member States*, Geneva: 24 August, document number: WT/DS79/R.
- WTO – Dispute Settlement Body (1998d), *Minutes of Meeting held in the Centre William Rappard on 22 September 1998*, Geneva: 20 October, document number: WT/DSB/M/48.
- WTO – Dispute Settlement Body (1998e), *Canada – Patent Protection of Pharmaceutical Products : Request for the Establishment of a Panel by the European Communities*, Geneva: 12 November, document number: WT/DS114/5.
- WTO – Dispute Settlement Body (1998f), *European Communities – Patent Protection for Pharmaceutical and Agricultural Chemical Products: Request for Consultations by Canada*, Geneva: 7 December, document number: WT/DS153/1.
- WTO – Dispute Settlement Body (1999a), *India – Patent Protection for Pharmaceutical and Agricultural Chemical Products – Status Report by India*, 16 April, document number: WT/DS50/10/Add.4.
- WTO – Dispute Settlement Body (1999b), *Minutes of Meeting held in the Centre William Rappard on 25 November 1998*, Geneva: 22 January, document number: WT/DSB/M/51.
- WTO – Dispute Settlement Body (2000a), *Canada – Patent Protection of Pharmaceutical Products: Complaint by the European Communities and their Member States*, Geneva: 17 March, document number: WT/DS114/R.

- WTO – Dispute Settlement Body (2000b), *Minutes of Meeting Held in the Centre William Rappard on 23 October 2000*, Geneva: 30 November, document number: WT/DSB/M91.
- WTO – General Council (1999a), *Preparations for the 1999 Ministerial Conference – EC Approach to Trade-Related Aspects of Intellectual Property Rights in the New Round, Communication from the European Communities*, Geneva: 2 June, document number: WT/GC/W/193.
- WTO – General Council (1999b), *Preparations for the 1999 Ministerial Conference – Proposal Regarding the TRIPs Agreement in terms of Paragraph 9(a)(i) of the Geneva Ministerial Declaration, Communication from India*, Geneva: 2 July, document number: WT/GC/W/225.
- WTO – General Council (1999c), *Preparations for the 1999 Ministerial Conference – Proposal on Trade-Related Aspects of Intellectual Property, Communication from Japan*, Geneva: 6 July, document number: WT/GC/W/242.
- WTO – General Council (1999d), *Preparations for the 1999 Ministerial Conference – Agreement on TRIPs: Extension of Additional Protection for Geographical Indications to other Products, Communication from Turkey*, Geneva: 13 July, document number: WT/GC/W/249.
- WTO – General Council (1999e), *Preparations for the 1999 Ministerial Conference Proposals Regarding the TRIPs Agreement (Paragraph 9(a)(ii) of the Geneva Ministerial Declaration), Communication from Venezuela*, Geneva, 6 August, document number: WT/GC/W/282.
- WTO – General Council (1999f), *Preparations for the 1999 Ministerial Conference – Extension of the Five-Year Period in Article 64.2 of the Agreement on TRIPs, Communication from Canada*, Geneva: 19 July, document number: WT/GC/W/256.
- WTO – General Council (1999g), *Preparations for the 1999 Ministerial Conference – Extension of the Five Year Period in Article 64.2 of the Agreement on TRIPs, Communication from the CEFTA and Latvia*, 27 July, document number: WT/GC/W/275.
- WTO – General Council (1999h), *Preparations for the 1999 Ministerial Conference – The TRIPs Agreement, from Kenya on Behalf of the African Group*, Geneva: 6 August, document number: WT/GC/W/302.
- WTO – General Council (1999i), *Preparations for the 1999 Ministerial Conference – Proposals Regarding the Agreement of Trade Related Aspects of Intellectual Property Rights, Communication from Colombia*, Geneva: 14 September, document number: WT/GC/W/316.
- WTO – General Council (1999j), *Preparations for the 1999 Ministerial Conference – Recommendation for Evaluation of Implementation Pursuant to Paragraph 8 of the Geneva Ministerial Declaration, Communication from the United States*, Geneva: 17 September, document number: WT/GC/W/323.

- WTO – General Council (1999k), *Preparations for the 1999 Ministerial Conference – Proposal on Protection of the Intellectual Property Rights Relating to the Traditional Knowledge of Local and Indigenous People, Communication from Cuba, Honduras, Paraguay and Venezuela*, Geneva: 22 September, document number: WT/GC/W/329.
- WTO – General Council (1999l), *Preparations for the 1999 Ministerial Conference – Transfer of Technology, Communication from India*, Geneva: 11 October, document number: WT/GC/W/352.
- WTO – General Council (1999m), *Preparations for the 1999 Ministerial Conference – Implementation Issues to be addressed in the First Year of Negotiations, Communication from Cuba, Dominican Republic, Egypt, El Salvador, Honduras, India, Indonesia, Malaysia, Nigeria, Pakistan, Sri Lanka and Uganda*, Geneva: 11 October, document number: WT/GC/W/355.
- WTO – General Council (1999n), *Preparations for the 1999 Ministerial Conference – Proposal on Protection of the Intellectual Property Rights Relating to the Traditional Knowledge of Local and Indigenous People, Communication from Bolivia, Colombia, Ecuador, Nicaragua and Peru*, Geneva: 12 October, document number: WT/GC/W/362.
- WTO – General Council (2001), *Preparations for the Fourth Session of the Ministerial Conference – Draft Declaration on Intellectual Property and [Access to Medicines][Public Health]*, Geneva: 27 October, document number: JOB(01)/155.
- WTO – Ministerial Conference (1996a), *Statement by H.E. Felipe Jaramillo, Vice Minister of Foreign Trade, Colombia*, 9 December, document number: WT/MIN(96)/ST/23.
- WTO – Ministerial Conference (1996b), *Statement by the Honourable K.G. Kgoroba, Minister of Commerce and Industry, Botswana*, 11 December, document number: WT/MIN(96)/ST/76.
- WTO – Ministerial Conference (1996c), *Statement by Mr Ruben Melgarejo Lanzoni, Minister of Foreign Relations, Paraguay*, 11 December, document number: WTO/MIN(96)/ST/75.
- WTO – Ministerial Conference, Second Session (1998a), *Commission of the European Communities: Statement Circulated by Sir Leon Brittan QC Vice President of the European Commission*, 18 May, document number: WT/MIN(98)/ST/76.
- WTO – Ministerial Conference, Second Session (1998b), *Statement Circulated by Mr Tofali Ahmed, Minister for Commerce and Industry, Bangladesh*, 18 May, document number: WT/MIN(98)/ST/60.
- WTO – Ministerial Conference, Second Session (1998c), *Statement Circulated by the Honourable J.J. Kamotho, Minister for Trade, Kenya*, 18 May, document number: WT/MIN(98)/ST/43.

- WTO – Ministerial Conference, Second Session (1998d), *Statement by the Honourable K.G. Kgoroba, Minister of Commerce and Industry, Botswana*, 20 May, document number: WT/MIN(98)/ST/110.
- WTO – Ministerial Conference, Second Session (1998e), *Statement Circulated by His Excellency Mr Luis Manuel Bonetti Veras, Secretary of State for Industry and Trade, Dominican Republic*, 20 May, document number: WT/MIN(98)/ST/117.
- WTO – Ministerial Conference, Third Session (1999a), *Statement by H.E. Mr Murasoli Maran, Minister of Commerce and Industry, India*, 30 November, document number: WT/MIN(99)/ST/16.
- WTO – Ministerial Conference, Third Session (1999b), *Statement by H.E. Mr Abdul Razak Dawood, Minister of Commerce, Industry and Production, Pakistan*, 30 November, document number: WT/MIN(99)/ST/9.
- WTO – Ministerial Conference, Third Session (1999c), *Statement by H.E. Mr Tofali Ahmad, M.P. Minister for Commerce and Industry, Bangladesh*, 30 November, document number: WT/MIN(99)/ST/17.
- WTO – Ministerial Conference, Third Session (1999d), *Statement by H.E. Mr Alami Tazi, Minister of Commerce, Industry and Handicrafts, Morocco*, 1 December, document number: WT/MIN(99)/ST/29.
- WTO – Ministerial Conference, Third Session (1999e), *Statement by H.E. Mr Khalifa Ababacar Sall, Minister of Commerce and Handicrafts, Senegal*, 1 December, document number: WT/MIN(99)/ST/61.
- WTO – Ministerial Conference, Third Session (1999f), *Statement by Dr Reginaldo Panting P., Secretary of State for Industry and Trade, Honduras*, 1 December, document number: WT/MIN(99)/ST/40.
- WTO – Ministerial Conference, Third Session (1999g), *Statement by H.E. Mr Malgari Bello Bouba, Minister for Industrial and Trade and Development, Cameroon*, 2 December, document number: WT/MIN(99)/ST/88.
- WTO – Ministerial Conference, Fourth Session (2001a), *Ministerial Declaration – Adopted on 14 November 2001*, 20 November, document number WT/MIN(01)/DEC/1.
- WTO – Ministerial Conference, Fourth Session (2001b), *Ministerial Declaration on the TRIPs Agreement and Public Health – Adopted on 14 November 2001*, 20 November, document number: WT/MIN(01)/DEC/2.
- WTO News (2001a), ‘Speech of the WTO’s Director General, Mr Mike Moore, in the 4th Ordinary Session of the OAU/AEC Conference of African Ministers of Trade’, Abuja: 22 September.
- WTO News (2001b), ‘Doha WTO Ministerial 2001: Summary of 11 November 2001’, Geneva: WTO website: [www.wto.org](http://www.wto.org), 11 November.
- WTO News (2001c), ‘Doha WTO Ministerial 2001: Summary of 12 November 2001’, Geneva: WTO website: [www.wto.org](http://www.wto.org), 12 November.

- WTO News (2001d), 'Doha WTO Ministerial 2001: Summary of 13 November 2001', Geneva: WTO website: [www.wto.org](http://www.wto.org), 13 November.
- WTO Secretariat (2000), 'Overview of the state of play of WTO Disputes', Geneva: 1 February.
- Yankey, G. Sipa-Adjah (1987), *International Patents and Technology Transfer to Less Developed Countries*, Aldershot: Avebury.
- Yin, R. (1994), *Case Study Research*, 3rd edn, Newbury Park: Sage.
- Yorke, B., Head of Corporate Intellectual Property, Novartis (1998), 'TRIPs implementation in the context of a possible Millennium Round', letter addressed to Mr Jerome P. Chauvin, UNICE, Geneva: Novartis, 5 November.
- Yorke, B. and E. Jucker (1992), 'Editorial', *News – Patents and Trademarks: Developments in Industrial Property Rights*, **21**, January, 1.
- Zimmerman, R. and M. Waldholz (2001), 'Abbott to sell Aids drugs at "No Profit" in Africa', *Wall Street Journal Europe*, 27 March.
- Zueco, T. (1999), 'Intellectual property', *The EU Committee of the American Chamber of Commerce – News Sheet*, Brussels: American Chamber of Commerce, June.
- Zuger, A. (1999), 'Fever pitch: getting doctors to prescribe is big business', *New York Times*, 11 January.